Tirilazad mesylate ophthalmic - InSite Vision
Alternative Names: ISV 600; Tirilazad mesylate - InSite VisionLatest Information Update: 22 Aug 2007
At a glance
- Originator Pharmacia Corporation
- Developer InSite Vision; Pharmacia Corporation
- Class Pregnatrienes
- Mechanism of Action Lipid peroxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cataracts; Diabetic retinopathy; Macular degeneration
Most Recent Events
- 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 01 Dec 1997 InSite Vision is seeking a corporate partner to enter clinical trials
- 01 Sep 1997 Preclinical development for Cataracts in USA (Ophthalmic)